Background Tissue factor pathway inhibitor 2 (TFPI-2) is a matrix-associated serine protease inhibitor with an enigmatic function in vivo. Here, we describe that TFPI-2 is present in fibrin of wounds and also expressed in skin, where it is up-regulated upon wounding. Methodology and Principal Findings Neutrophil elastase cleaved TFPI-2, and a C-terminal fragment was found to bind to bacteria. Similarly, a prototypic peptide representing this C-terminal part, EDC34, bound to bacteria and bacterial lipopolysaccharide, and induced bacterial permeabilization. The peptide also induced leakage in artificial liposomes, and displayed a random coil conformation upon interactions with liposomes as well as lipopolysaccharide. EDC34 was antibacterial against both Gram-negative and Gram-positive bacteria in physiological buffer conditions. Conclusions/Significance The results demonstrate that the C-terminus of TFPI-2 encodes for antimicrobial activity, and may be released during wounding.
References
[1]
Boman HG (2003) Antibacterial peptides: basic facts and emerging concepts. J Intern Med 254: 197–215.
[2]
Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415: 389–395.
[3]
Lehrer RI, Ganz T (2002) Defensins of vertebrate animals. Curr Opin Immunol 14: 96–102.
[4]
Oppenheim JJ, Yang D (2005) Alarmins: chemotactic activators of immune responses. Curr Opin Immunol 17: 359–365.
[5]
Harder J, Schroder JM (2005) Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 77: 476–486.
[6]
Glaser R, Harder J, Lange H, Bartels J, Christophers E, et al. (2005) Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol 6: 57–64.
[7]
Nordahl EA, Rydengard V, Nyberg P, Nitsche DP, Morgelin M, et al. (2004) Activation of the complement system generates antibacterial peptides. Proc Natl Acad Sci U S A 101: 16879–16884.
[8]
Papareddy P, Rydengard V, Pasupuleti M, Walse B, Morgelin M, et al. (2010) Proteolysis of human thrombin generates novel host defense peptides. PLoS Pathog 6: e1000857.
[9]
Frick IM, Akesson P, Herwald H, Morgelin M, Malmsten M, et al. (2006) The contact system–a novel branch of innate immunity generating antibacterial peptides. EMBO J 25: 5569–5578.
[10]
Malmstrom E, Morgelin M, Malmsten M, Johansson L, Norrby-Teglund A, et al. (2009) Protein C inhibitor–a novel antimicrobial agent. PLoS Pathog 5: e1000698.
[11]
Tang YQ, Yeaman MR, Selsted ME (2002) Antimicrobial peptides from human platelets. Infect Immun 70: 6524–6533.
[12]
Riedel T, Suttnar J, Brynda E, Houska M, Medved L, et al. (2011) Fibrinopeptides A and B release in the process of surface fibrin formation. Blood 117: 1700–1706.
[13]
Papareddy P, Kalle M, Kasetty G, Morgelin M, Rydengard V, et al. (2010) C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem 285: 28387–28398.
[14]
Chand HS, Foster DC, Kisiel W (2005) Structure, function and biology of tissue factor pathway inhibitor-2. Thromb Haemost 94: 1122–1130.
[15]
Sprecher CA, Kisiel W, Mathewes S, Foster DC (1994) Molecular cloning, expression, and partial characterization of a second human tissue-factor-pathway inhibitor. Proc Natl Acad Sci U S A 91: 3353–3357.
[16]
Udagawa K, Miyagi Y, Hirahara F, Miyagi E, Nagashima Y, et al. (1998) Specific expression of PP5/TFPI2 mRNA by syncytiotrophoblasts in human placenta as revealed by in situ hybridization. Placenta 19: 217–223.
[17]
Iino M, Foster DC, Kisiel W (1998) Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Arterioscler Thromb Vasc Biol 18: 40–46.
[18]
Rao CN, Liu YY, Peavey CL, Woodley DT (1995) Novel extracellular matrix-associated serine proteinase inhibitors from human skin fibroblasts. Arch Biochem Biophys 317: 311–314.
[19]
Rao CN, Peavey CL, Liu YY, Lapiere JC, Woodley DT (1995) Partial characterization of matrix-associated serine protease inhibitors from human skin cells. J Invest Dermatol 104: 379–383.
[20]
Rao CN, Reddy P, Liu Y, O’Toole E, Reeder D, et al. (1996) Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Arch Biochem Biophys 335: 82–92.
[21]
Rao CN, Gomez DE, Woodley DT, Thorgeirsson UP (1995) Partial characterization of novel serine proteinase inhibitors from human umbilical vein endothelial cells. Arch Biochem Biophys 319: 55–62.
[22]
Petersen LC, Sprecher CA, Foster DC, Blumberg H, Hamamoto T, et al. (1996) Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Biochemistry 35: 266–272.
[23]
Kong D, Ma D, Bai H, Guo H, Cai X, et al. (2004) Expression and characterization of the first kunitz domain of human tissue factor pathway inhibitor-2. Biochem Biophys Res Commun 324: 1179–1185.
[24]
Hisaka T, Lardeux B, Lamireau T, Wuestefeld T, Lalor PF, et al. (2004) Expression of tissue factor pathway inhibitor-2 in murine and human liver regulation during inflammation. Thromb Haemost 91: 569–575.
[25]
Torres-Collado AX, Kisiel W, Iruela-Arispe ML, Rodriguez-Manzaneque JC (2006) ADAMTS1 interacts with, cleaves, and modifies the extracellular location of the matrix inhibitor tissue factor pathway inhibitor-2. J Biol Chem 281: 17827–17837.
[26]
Carlemalm E, Villiger W, Hobot JA, Acetarin JD, Kellenberger E (1985) Low temperature embedding with Lowicryl resins: two new formulations and some applications. J Microsc 140: 55–63.
[27]
Roupe KM, Nybo M, Sjobring U, Alberius P, Schmidtchen A, et al. (2010) Injury is a major inducer of epidermal innate immune responses during wound healing. J Invest Dermatol 130: 1167–1177.
[28]
Parkinson H, Kapushesky M, Kolesnikov N, Rustici G, Shojatalab M, et al. (2009) ArrayExpress update–from an archive of functional genomics experiments to the atlas of gene expression. Nucleic Acids Res 37: D868–872.
[29]
Tossi A, Sandri L, Giangaspero A (2000) Amphipathic, alpha-helical antimicrobial peptides. Biopolymers 55: 4–30.
[30]
Brogden KA (2005) Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3: 238–250.
[31]
Huang HW (2006) Molecular mechanism of antimicrobial peptides: the origin of cooperativity. Biochim Biophys Acta 1758: 1292–1302.
[32]
Stromstedt AA, Wessman P, Ringstad L, Edwards K, Malmsten M (2007) Effect of lipid headgroup composition on the interaction between melittin and lipid bilayers. J Colloid Interface Sci 311: 59–69.
[33]
Ramamoorthy A, Thennarasu S, Lee DK, Tan A, Maloy L (2006) Solid-state NMR investigation of the membrane-disrupting mechanism of antimicrobial peptides MSI-78 and MSI-594 derived from magainin 2 and melittin. Biophys J 91: 206–216.
[34]
Ringstad L, Andersson Nordahl E, Schmidtchen A, Malmsten M (2007) Composition effect on peptide interaction with lipids and bacteria: variants of C3a peptide CNY21. Biophys J 92: 87–98.
[35]
Ringstad L, Kacprzyk L, Schmidtchen A, Malmsten M (2007) Effects of topology, length, and charge on the activity of a kininogen-derived peptide on lipid membranes and bacteria. Biochim Biophys Acta 1768: 715–727.
[36]
Ringstad L, Schmidtchen A, Malmsten M (2006) Effect of Peptide Length on the Interaction between Consensus Peptides and DOPC/DOPA Bilayers. Langmuir 22: 5042–5050.
[37]
Ringstad L, Protopapa E, Lindholm-Sethson B, Schmidtchen A, Nelson A, et al. (2008) An electrochemical study into the interaction between complement-derived peptides and DOPC mono- and bilayers. Langmuir 24: 208–216.
[38]
Chen FY, Lee MT, Huang HW (2003) Evidence for membrane thinning effect as the mechanism for peptide-induced pore formation. Biophys J 84: 3751–3758.
[39]
Nordahl EA, Rydeng？rd V, M？rgelin M, Schmidtchen A (2005) Domain 5 of high molecular weight kininogen is antibacterial. J Biol Chem 280: 34832–34839.
